Natera, Inc. (NTRA) slumps 19% after Q3 earnings miss
Natera, Inc. (NTRA) slumps after reporting stronger revenue but a wider-than-expected quarterly loss and an immediate CEO transition. Investors are weighing solid guidance, rising oncology testing volume, and clinical momentum against the earnings miss, higher expenses, and leadership uncertainty.
Natera, Inc. (NTRA) slumped sharply after hours after reporting third-quarter EPS of -$0.42, well below estimates, even as revenue and full-year guidance improved. The selloff reflects investor concern over profitability, rising operating costs, and an immediate CEO transition, which outweighed the company’s strong growth in oncology testing and positive outlook. For investors, the move signals that NTRA still needs to prove it can convert rapid revenue growth into durable earnings power.
Natera, Inc. (NTRA) slumps 19.49% to $292.85 in after-hours trading after reporting a sharper-than-expected third-quarter loss and an immediate CEO transition. Revenue and guidance were strong, but the market focused on quarterly EPS of -$0.42 versus a -$0.17 estimate; because this is an extended-hours move, regular-session trading will confirm whether the decline holds.
Key Takeaways
NTRA fell from a $363.76 regular-session reference to $292.85 after hours, a 19.49% decline.
The main catalyst was Q3 revenue of $794.0 million, EPS of -$0.42, and a $140 million midpoint increase to 2026 revenue guidance.
Solomon Moshkevich became CEO effective immediately as Steve Chapman stepped down, adding leadership risk to the earnings reaction.
Revenue and oncology testing remain strong, but losses, operating costs, revenue true-ups, and a $52.43 billion market cap leave little room for disappointment.
Why Natera Stock Is Slumping After Q3 Earnings
The most likely catalyst is Natera's third-quarter 2026 earnings report, issued on November 5. The company posted revenue of $794.0 million, up 34.1% from $592.2 million a year earlier. However, diluted EPS came in at -$0.42, below the -$0.17 estimate listed in the earnings history.
That earnings miss matters because NTRA trades as a premium growth stock. Investors often tolerate losses when growth accelerates and the path to cash generation becomes clearer. A larger-than-expected loss does the opposite, especially after the stock traded between $277.00 and $392.00 during the regular session and volume reached 3.16 million shares.
The same announcement included a major leadership change. Solomon Moshkevich was appointed chief executive officer and joined the board effective immediately. Steve Chapman stepped down from the CEO role. The timing gives traders a second reason to reduce exposure: Natera raised its outlook, but the person responsible for leading its next expansion phase changed on the same day.
Natera also raised its 2026 revenue guidance from $2.850 billion to $2.910 billion to $3.005 billion to $3.035 billion. The midpoint increased by $140 million, and management guided to positive cash flow for the year. Those figures explain why the reaction looks confusing at first glance. The business outlook improved, yet the stock sold off because investors judged the earnings quality and leadership change more harshly than the guidance increase.
Natera Financials Show Growth Without Consistent Profitability
Natera's operating growth remains substantial. The company processed about 1,093,100 tests in the quarter, up 22.3% year over year. Oncology tests reached approximately 339,500, a 60.9% increase from 211,000 in the prior-year quarter. That oncology performance supports the investment case for Signatera, the company's personalized circulating tumor DNA test.
Profitability, however, remains the weak link. Natera reported a net loss of $59.9 million, or -$0.42 per diluted share, compared with a $87.5 million loss, or -$0.64 per share, a year earlier. The loss improved, but the company still did not reach profitability. Operating expenses rose 19.5% to $576.1 million.
Gross margin was 64.7%, roughly flat year over year. Natera said non-GAAP gross margin excluding revenue true-ups improved 137 basis points sequentially from the second quarter. At the same time, changes in estimates increased revenue and gross profit during the quarter. That accounting factor can make investors more cautious when they assess how much of the reported improvement reflects repeatable operating performance.
The earnings history adds pressure. Natera recorded only two earnings beats across seven quarters. Recent results included EPS of -$0.47 in August and -$0.60 in May. Therefore, the latest loss landed in a market already sensitive to execution rather than willing to reward growth alone.
NTRA Valuation and Signatera Competitive Position After the Drop
Natera has a $52.43 billion market cap and a beta of 1.515. With negative EPS, a standard price-to-earnings measure provides little support for the valuation. Instead, the market values NTRA on revenue growth, test volume, clinical adoption, and its eventual cash generation.
The competitive argument centers on Signatera and the broader precision medicine platform. Natera offers oncology tests such as Signatera, Latitude, and Altera, alongside Empower hereditary cancer screening. Signatera received Medicare coverage for hepatocellular carcinoma through the CMS MolDX program on November 3. On November 4, three peer-reviewed publications reported recurrence detection ahead of imaging by a median of 4.3 months, with cited sensitivity of 91.7% and specificity of 96.4%.
Those developments strengthen the long-term adoption story. The latest SITC data also linked ctDNA clearance with long-term survival across four metastatic cancers. Still, clinical evidence must translate into reimbursed testing, rising margins, and consistent profits. That is where the market is demanding proof.
Analyst sentiment remains positive, with 25 Buy ratings, three Hold ratings, and no Sell ratings in the latest consensus data. The consensus price target is $386, with targets ranging from $245 to $500. That wide range signals optimism about Natera's platform, but it does not make any target a floor for the stock.
What NTRA Investors Should Do With the Earnings Reset
The practical approach is to separate the business scorecard from the stock scorecard. The business scorecard includes 34.1% revenue growth, 60.9% oncology test growth, a 64.7% gross margin, and positive cash flow guidance. The stock scorecard includes the -$0.42 EPS result, the leadership transition, and the market's willingness to pay for growth while the company remains loss-making.
The $292.85 after-hours print should serve as a risk reference, not a confirmed valuation floor. Investors can compare regular-session trading with the $363.76 prior reference and track whether the price reaction matches the underlying guidance improvement. A durable recovery needs more than a strong revenue number. It needs evidence that test growth, margin improvement, and cash generation can overcome elevated expenses and repeated EPS pressure.
Natera's after-hours slump is an earnings reset amplified by an immediate CEO change, not evidence of collapsing demand. Revenue, oncology testing, Medicare coverage, and clinical data support the growth story, while the EPS miss, operating costs, and negative earnings explain why NTRA remains vulnerable to sharp repricing.
Natera shares are down because the company reported a larger-than-expected quarterly loss, with EPS of -$0.42 versus a -$0.17 estimate. The market also reacted to the immediate CEO transition, even though revenue and guidance were strong.
+Should I buy NTRA stock now?
The article suggests caution rather than an immediate buy. Natera has strong growth and improving guidance, but the stock is still being penalized for losses, elevated expenses, and execution risk.
+Did Natera beat on revenue in Q3?
Yes. Natera reported Q3 revenue of $794.0 million, which was up 34.1% year over year and supported a higher 2026 outlook. The stock still sold off because earnings missed expectations by a wide margin.
+What does the CEO change mean for NTRA investors?
The immediate CEO transition adds uncertainty at a sensitive moment for the stock. It does not change the growth story, but it raises the bar for management to prove consistent execution and profitability.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on NTRA?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
